Evidence map›Paper›PMID 33865457›Full record

ArticleEye and vision (London, England)2021

Anti-VEGF therapy prevents Müller intracellular edema by decreasing VEGF-A in diabetic retinopathy.

Tianqin Wang, Chaoyang Zhang, Hai Xie, Mengmeng Jiang, Haibin Tian, Lixia Lu, Guo-Tong Xu, Lin Liu, Jingfa Zhang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Eye and vision (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. The Role of Müller Cells in Diabetic Macular Edema.Investigative ophthalmology & visual science · 2023
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Tianqin WangDepartment of Ophthalmology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 160 Pujian Road, Pudong New District, Shanghai, 200127, China.
Chaoyang ZhangDepartment of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University, 100 Haining Road, Hongkou District, Shanghai, 200080, China.
Hai XieTongji Eye Institute, Tongji University School of Medicine, 1239 Siping Road, Medical School Building, Room 623, Shanghai, 200092, China.
Mengmeng JiangDepartment of Ophthalmology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 160 Pujian Road, Pudong New District, Shanghai, 200127, China.
Haibin TianTongji Eye Institute, Tongji University School of Medicine, 1239 Siping Road, Medical School Building, Room 623, Shanghai, 200092, China.
Lixia LuTongji Eye Institute, Tongji University School of Medicine, 1239 Siping Road, Medical School Building, Room 623, Shanghai, 200092, China.
Guo-Tong Xu *Tongji Eye Institute, Tongji University School of Medicine, 1239 Siping Road, Medical School Building, Room 623, Shanghai, 200092, China. gtxu@tongji.edu.cn.
Lin Liu *Department of Ophthalmology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 160 Pujian Road, Pudong New District, Shanghai, 200127, China. 18918358758@163.com.
Jingfa Zhang *Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University, 100 Haining Road, Hongkou District, Shanghai, 200080, China. 13917311571@139.com.ORCID http://orcid.org/0000-0003-0601-4342
Shanghai Jiao Tong University · CNTongji University · CNShanghai Eye Disease Prevention & Treatment Center · CN

Funding

National Major Scientific and Technological Special Project for "Significant New Drugs Development" during the Thirtieth Five-year Plan Period 2019ZX09301113National Natural Science Foundation of China 81570852National Natural Science Foundation of China 81970810National Natural Science Foundation of China 81970811
6 · The paper itself

Abstract

backgroundAlthough vascular endothelial growth factor A (VEGF-A) is known to play a key role in causing retinal edema, whether and how VEGF-A induces intracellular edema in the retina still remains unclear.

methodsSprague-Dawley rats were rendered diabetic with intraperitoneal injection of streptozotocin. Intravitreal injection of ranibizumab was performed 8 weeks after diabetes onset. rMC-1 cells (rat Müller cell line) were treated with glyoxal for 24 h with or without ranibizumab. The expression levels of inwardly rectifying K

resultsCompared with normal control, protein expressions of Kir4.1 and AQP4 were down-regulated significantly in diabetic rat retinas, which were prevented by ranibizumab. The above changes were recapitulated in vitro. Similarly, the intracellular potassium level in glyoxal-treated rMC-1 cells was increased, while the intracellular sodium level and Na

conclusionRanibizumab protected Müller cells from diabetic intracellular edema through the up-regulation of Kir4.1 and AQP4 by directly binding VEGF-A. It also caused a reduction in intracellular osmotic pressure.

Indexed as

Anti-VEGFDiabetic macular edemaDiabetic retinopathyIntracellular edemaMüller cell

Identifiers

PMID33865457
PMCPMC8053282
OpenAlexW3154146366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.